eriodictyol has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apostolides, Z; Bester, MJ; Tolmie, M | 1 |
| Ahn, MJ; Han, JH; Jung, SH; Kim, IS; Kim, Y; Lee, JJ; Lee, SG; Myung, CS; Zhang, WY | 1 |
2 other study(ies) available for eriodictyol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Inhibition of α-glucosidase and α-amylase by herbal compounds for the treatment of type 2 diabetes: A validation of in silico reverse docking with in vitro enzyme assays.
Topics: Acarbose; Alkaloids; alpha-Amylases; alpha-Glucosidases; Apigenin; Benzodioxoles; Chemical Phenomena; Computer Simulation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Flavanones; Glycoside Hydrolase Inhibitors; Hep G2 Cells; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Piperidines; Plants, Medicinal; Polyunsaturated Alkamides; Spices | 2021 |
Effect of eriodictyol on glucose uptake and insulin resistance in vitro.
Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 2; Fatty Acid-Binding Proteins; Flavanones; Gene Expression; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Peroxisome Proliferator-Activated Receptors | 2012 |